Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models

Statistics in Medicine

Volumn 31, Issue 11-12, 2012, Pages 1043-1058

  Nguyen, Thu Thuy ^a   Bazzoli, Caroline ^a   Mentré, France ^a  

^a INSERM   (France)

Author keywords

Crossover; Design; Fisher information matrix; Nonlinear mixed effects models; Power; Sample size

Indexed keywords

AMOXICILLIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COVARIANCE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; ERROR; NONHUMAN; NONLINEAR SYSTEM; PROCESS OPTIMIZATION; SAMPLE SIZE; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STUDY DESIGN; TREATMENT OUTCOME;

ALGORITHMS; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; CROSS-OVER STUDIES; HUMANS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PHARMACOKINETICS; RESEARCH DESIGN; SAMPLE SIZE; SWINE; THERAPEUTIC EQUIVALENCY;

EID: 84861190766     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4390     Document Type: Article

References (42)

1. FDA. Guidance for industry: statistical aproaches to establishing bioequivalence, Technical Report, FDA, 2001.
2. EMEA. Note for guidance on the investigation of bioavailability and bioequivalence, Technical Report, EMEA, 2001.
3. Hauschke D, Steinijans V, Pigeot I. Bioequivalence Studies in Drug Development. John Wiley & Sons:Chichester, 2007.
4. Gabrielson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 4th ed. Swedish Pharmaceutical Press:Stockholm, 2006.
5. Yeh C. Estimation and significant tests of area under the curve derived from incomplete blood sampling. American statistical association proceedings of the biopharmaceutical section, 1990;74-81.
6. Jaki T, Wolfsegger MJ.A theoretical framework for estimation of aucs in complete and incomplete sampling designs. Statistics in Biopharmaceutical Research 2009;1:176-184. DOI: 10.1198/sbr.2009.0025.
7. Jaki T, Wolfsegger MJ, Lawo J-P. Establishing bioequivalence in complete and incomplete data designs using aucs. Journal of Biopharmaceutical Statistic 2010;20:803-820.
8. Jusko WJ, Koup JR, Alvan G. Nonlinear assessment of phenytoin bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 1976;4:327-336. DOI: 10.1007/BF01063122.
9. Hayashi N, Aso H, Higashida M, Kinoshita H, Ohdo S, Yukawa E, Hiquchi S. Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner-Nelson method with a nonlinear elimination model. European Journal of Pharmaceutical Sciences 2001;13:151-158. DOI: 10.1016/S0928-0987(00)00219-0.
10. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Computers and Biomedical Research 1972;5:411-459. DOI: 10.1016/0010-4809(72)90051-1.
11. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modelling in drug development. Annual Review of Pharmacology and Toxicology 2000;40:67-95. DOI: 10.1146/annurev.pharmtox.40.1.67.
12. Panhard X, Taburet AM, Piketti C, Mentré F. Impact of modeling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients. Statistics in Medicine 2007;26:1268-1284. DOI: 10.1002/sim.2622.
13. Dubois A, Gsteiger S, Pigeolet E, Mentré F. Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs. Pharmaceutical Research 2010;27:92-110. DOI: 10.1007/s11095-009-9980-5.
14. Dubois A, Lavielle M, Gsteiger S, Pigeolet E, Mentré F. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Statistics in Medicine 2011;30:2582-2600. DOI: 10.1002/sim.4286.
15. Al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1990;18:347-360. DOI: 10.1007/BF01062273.
16. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. Journal of Pharmacokinetics and Biopharmaceutics 1991'19:333-353. DOI: 10.1007/BF03036255.
17. Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1996;24:245-263. DOI: 10.1007/BF02353491.
18. Atkinson AC, Donev AN. Optimum Experimental Designs, Oxford Statistical Science. Clarendon Press:Oxford, 1992.
19. Walter E, Pronzato L. Identification of Parametric Models from Experimental Data. Springer:New York, 2007.
20. Mentré F, Mallet A, Baccar D. Optimal design in random effect regression models. Biometrika 1997;84:429-442. DOI: 10.1093/biomet/84.2.429.
21. Bazzoli C, Retout S, Mentré F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Computer Methods and Programs in Biomedicine 2010;98:55-65. DOI: 10.1016/j.cmpb.2009.09.012.
22. Hooker A, Vicini P. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. American Association of Pharmaceutical Scientists Journal 2005;7:759-785. DOI: 10.1208/aapsj070476.
23. Gueorguieva I, Aarons L, Ogungbenro K, Jorga KM, Rodgers T, Rowland M. Optimal design for multivariate response pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 2006;33:97-124. DOI: 10.1007/s10928-006-9009-1.
24. Ogungbenro K, Gueorguieva I, Majid O, Graham G, Aarons L. Optimal design for multiresponse pharmacokinetic-pharmacodynamic models-dealing with unbalanced designs. Journal of Pharmacokinetics and Pharmacodynamics 2007;34:313-331. DOI: 10.1007/s10928-006-9048-7.
25. Ogungbenro K, Graham G, Gueorguieva I, Aarons L. Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments. Journal of Biopharmaceutical Statistics 2008;18:342-358. DOI: 10.1080/10543400701697208.
26. Bazzoli C, Retout S, Mentré F. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model. Statistics in Medicine 2009;28:1940-1956. DOI: 10.1002/sim.3573.
27. Mentré F, Duffull S, Gueorguieva I, Hooker A, Leonov S, Ogungbenro K, Retout S. Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison. 16th Population Approach Group in Europe. Copenhagen, Denmark, 2007. Abstract 1179.
28. Karlsson MO, Sheiner LB. The importance of modelling the inter-occasion variability in population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1993;21:735-750. DOI: 10.1007/BF01113502.
29. Retout S, Mentré F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 2003;13:209-227. DOI: 10.1081/BIP-120019267.
30. Retout S, Comets E, Samson A, Mentré F. Design in nonlinear mixed effects models: optimisation using the Fedorov-Wynn algorithm and power of the wald test for binary covariates. Statistics in Medicine 2007;26:5162-5179. DOI: 10.1002/sim.2910.
31. Mielke T, Schwabe R. Some considerations on the Fisher information in nonlinear mixed effects models. Proceedings of the 9th international workshop in model-oriented design and analysis, Bertinoro, Italy, 2010.
32. Panhard X, Mentré F. Evaluation by simulation of tests based on non-linear mixed effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Statistics in Medicine 2005;24:1509-1524. DOI: 10.1002/sim.2047.
33. Schuirmann DJ.A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 1987;15:657-680. DOI: 10.1007/BF01068419.
34. Fedorov V. Theory of Optimal Experiments. Academic Press:New York, 1972.
35. Wynn HP. Results in the theory and construction of D-optimum designs. Journal of the Royal Statistical Society B 1972;34:133-147.
36. Delyon B, Lavielle M, Moulines E. Convergence of a stochastic approximation version of EM algorithm. The Annals of Statistics 1999;27:94-128. DOI: 10.1214/aos/1018031103.
37. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects model. Computational Statistics and Data Analysis 2004;49:1020-1038. DOI: 10.1016/j.csda.2004.07.002.
38. Samson A, Lavielle M, Mentré F. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed effects model. Statistics in Medecine 2007;26:4860-4875. DOI: 10.1002/sim.2950.
39. Panhard X, Samson A. Extension of the SAEM algorithm for nonlinear mixed effects models with two levels of random effects. Biostatistics 2009;10:121-135. DOI: 10.1093/biostatistics/kxn020.
40. Samson A, Lavielle M, Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Computational Statistics and Data Analysis 2006;51:1562-1574. DOI: 10.1016/j.csda.2006.05.007.
41. Gagnon R, Leonov S. Optimal population designs for PK models with serial sampling. Journal of Biopharmaceutical Statistics 2005;15:143-163. DOI: 10.1081/BIP-200040853.
42. Guedj J, Bazzoli C, Neumann AU, Mentré F. Design evaluation and optimisation for models of hepatitis C viral dynamics. Statistics in Medicine 2011;30:1045-1056. DOI: 10.1002/sim.4191.